Why the study?
Does vildagliptin monotherapy improve glycemic control compared to gliclazide in drug-naïve patients with type 2 diabetes?
Does vildagliptin monotherapy improve glycemic control compared to gliclazide in drug-naïve patients with type 2 diabetes?
Vildagliptin monotherapy did not meet statistical noninferiority to gliclazide for HbA1c reduction at 2 years, but was associated with significantly less weight gain and lower rates of mild hypoglycemia.
Answers are grounded in this paper and cite their sources.
Vildagliptin fails noninferiority to gliclazide for HbA1c reduction at 2 years; challenges its role as first-line monotherapy in drug-naïve type 2 diabetes.
This report is part of the overall evaluation of using vildagliptin in the treatment of type 2 diabetes. Here the results of a multi-center, double-blind, randomized, active-controlled study designed to compare the efficacy and safety of two years of monotherapy with vildagliptin 50 mg bid and gliclazide up to 320 mg/day in drug-naïve patients with type 2 diabetes are reported. A total of 546 patients were randomized and approximately 74% of patients completed the study in each group. HbA (1c) values were slightly higher in the gliclazide group (HbA (1c) of 8.7+/-0.1% vs. 8.5+/-0.1% in the vildagliptin group). The mean reduction in HbA (1c) from baseline to Week 104 was -0.5% in the vildagliptin group and -0.6% in the gliclazide group. The associated 95% confidence interval (CI) for the between-group difference (0.13%) in mean change was (-0.06%, 0.33%). Thus, noninferiority based on an upper limit of the CI of 0.3% was not met. In the vildagliptin group, weight increased by 0.8+/-0.2 kg compared to 1.6+/-0.2 kg in the gliclazide group (p<0.01). Mild hypoglycemia was recorded in 0.7% of patients in the vildagliptin group and in 1.7% in the gliclazide group. Both drugs were well tolerated. In summary, vildagliptin monotherapy resulted in improved glycemic control in drug-naïve patients with type 2 diabetes. Although the hypothesis of noninferiority to gliclazide was not borne out statistically, the reductions in HbA (1c) were similar over a two year period and vildagliptin had significant benefits in terms of less weight gain and less hypoglycemia.
No takes yet. Share an insight, caveat, or question.
Foley et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: